Arrowhead Research | ARWR - Srodki Pieniężne I Ekwiwalent





Srodki Pieniężne I Ekwiwalent Zmiana Data
Agios Pharmaceuticals USD 99.65M 13.95M 2026-06
Alnylam Pharmaceuticals USD 1.71B 2.46M 2026-06
Anika Therapeutics USD 38.41M 2.61M 2026-06
Arrowhead Research USD 19.68M 127.85M 2026-06
Heron Therapeutics USD 20.72M 5.4M 2026-06
Incyte USD 3.98B 33.45M 2026-06
Ionis Pharmaceuticals USD 350.06M 1.57B 2026-06
Ligand Pharmaceuticals USD 1.01B 891.62M 2026-06
Merck USD 6.85B 1.52B 2026-06
Moderna USD 1.72B 185M 2026-06
Nektar Therapeutics USD 149.58M 134.46M 2026-03
Novartis USD 7.62B 739M 2026-06
Sarepta Therapeutics USD 571.15M 106.7M 2026-06
TG Therapeutics USD 612.25M 170.04M 2026-06
Ultragenyx Pharmaceutical USD 125M 50M 2026-06
Vertex Pharmaceuticals USD 7.85B 605.7M 2026-06
Xencor USD 44.66M 30.49M 2026-06